On August 22, 2022 Avenge Bio, Inc., ("Avenge" or the "Company") a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, reported a publication in the peer-reviewed journal Clinical Cancer Research describing the foundational, preclinical data establishing the efficacy and safety of pleural administered LOCOcyte for the treatment of pleural malignant mesothelioma (Press release, Avenge Bio, AUG 22, 2022, View Source [SID1234618554]). The manuscript, entitled "Activation of adaptive and innate immune cells via localized Interleukin-2 cytokine factories eradicates mesothelioma tumors," was published today and can be viewed on the Clinical Cancer Research website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Malignant mesothelioma and lung cancers which have metastasized to the pleural cavity remain particularly deadly with median survival times of less than a one year. Mesothelioma affects the organs that are lined by the mesothelium including the organs of the chest (pleura) and abdomen (peritoneum). It is a highly aggressive cancer and is essentially lethal in all cases. Despite recent advances in therapies to treat malignant mesothelioma, optimal and safe delivery remains a challenge. Current therapeutic options are of limited efficacy in both early and late-stage disease. Immunotherapies, including the use of PD-1 inhibitors, delivered systemically, have been shown to marginally extend patient survival. To overcome this challenge, a research team at Rice University led by Professor Omid Veiseh, Ph.D., has developed an innovative immunotherapy platform that enables engineered cells to produce immune-activating molecules, for a specified duration, within this fluid tumor microenvironment.
The Clinical Cancer Research manuscript details the LOCOcyte platform and its safety and efficacy in preclinical models. The human cells are engineered to produce murine immune cell signaling molecule interleukin-2 (IL2), a critical cytokine that initiates a robust localized immune response when administered into the pleural cavity of tumor-bearing mice that model advanced malignant mesothelioma. Overall, we observed a significant reduction of tumor burden in mice treated with IL2 monotherapy and complete eradication of tumor burden in mice treated with IL2 and an immune checkpoint inhibitor combination therapy.
"The continued occurrence of malignant mesothelioma necessitates the clinical assessment of new, effective treatments. Thus, the potential of the IL-2 cytokine factory for the treatment of malignant mesothelioma highlights the urgency of its evaluation in clinical trials," said Dr. Veiseh, Assistant Professor of Bioengineering at Rice University and a Founder of Avenge Bio.
Dr. Bryan Burt, Chief of the Division of Thoracic Surgery at Baylor College of Medicine, commented, "Pleural mesothelioma is a devastating malignancy that has traditionally defeated standard therapies. Whereas immune checkpoint blockade has recently demonstrated an encouraging signal in patients with unresectable disease, most patients still do not respond to therapy and systemic immune-related adverse events remain significant. Local delivery of a therapeutic can reduce toxicity by confining the immunostimulatory effects to local tumor microenvironment, highlighting a strong rationale for developing Avenge’s LOCOcyte platform."
Avenge Bio has an exclusive license from Rice University for this technology. In July 2022, Avenge announced that Food and Drug Administration ("FDA") cleared the Investigational New Drug ("IND") application for AVB-001 for the treatment of platinum resistance ovarian cancer. The Phase 1, multi-center clinical trial is expected to be initiated in the second half of 2022.
About LOCOcyte Platform
Our LOCOcyte allogeneic cell-based immunotherapy platform enables potent localized modulation of the immune system which also precipitates a systemic immune response, allowing us to treat previously intractable cancers. The technology leverage three unique advantages:
(1)Potent immune effector molecules are generated by synthetically engineering allogeneic cells creating a ready-to-use therapy,
(2) Therapy is localized in proximity to the primary tumor site and generates innate and adaptive immune response, and
(3) The immunomodulator trains the patient’s immune system generating a robust immune response that seeks and eradicates distal metastasis without systemic toxicity.